Avalo Therapeutics announces active IND for AVTX-009

Avalo Therapeutics announced that the Investigational New Drug, IND, for AVTX-009, an anti-IL-1beta monoclonal antibody, for the treatment of hidradenitis suppurativa is now active, permitting the Company to commence its Phase 2, LOTUS, clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year. “This active IND is an important step for commencing the LOTUS trial in patients with hidradenitis suppurativa. I am proud of the Avalo team for achieving this milestone in just over three months from acquiring the product candidate in late March 2024,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “We believe that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing, and we look forward to getting the LOTUS Trial underway.”